How to buy Bausch + Lomb Corporation stock (Bausch + Lomb Corporation)

Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, has gone public with an IPO. Shares were priced at $18, below the expected range. and rose slightly to around $19 in their first morning of trading on May 6.

Our top picks for where to buy Bausch + Lomb stock

Buy Bausch + Lomb Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bausch + Lomb Corporation stock price (NYSE: BLCO)

Use our graph to track the performance of BLCO stocks over time.

Bausch + Lomb Corporation shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$17.86
52-week range	$13.16 - $21.69
50-day moving average more info button	$19.71
200-day moving average more info button	$16.97
Wall St. target price	$21.06
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.04

Is it a good time to buy Bausch + Lomb Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bausch + Lomb Corporation price performance over time

Historical closes compared with the close of $17.86 from 2024-12-24

1 week (2024-12-19)	-0.50%
1 month (2024-11-26)	-9.57%
3 months (2024-09-26)	-6.20%
6 months (2024-06-26)	20.92%

1 year (2023-12-26)	12.12%
2 years (2022-12-23)	21.99%
3 years (2021-12-22)	N/A
5 years (2019-12-22)	N/A

Is Bausch + Lomb Corporation stock undervalued or overvalued?

Valuing Bausch + Lomb Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bausch + Lomb Corporation's PEG ratio

Bausch + Lomb Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6992. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bausch + Lomb Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bausch + Lomb Corporation's PEG ratio in relation to those of similar companies.

• The Cooper Companies IncCommon Stock (COO.US): 9.89
• Johnson-and-Johnson (JNJ.US): 0.87

Bausch + Lomb Corporation's EBITDA

Bausch + Lomb Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $635 million.

The EBITDA is a measure of a Bausch + Lomb Corporation's overall financial performance and is widely used to measure a its profitability.

To put Bausch + Lomb Corporation's EBITDA into context you can compare it against that of similar companies.

• The Cooper Companies IncCommon Stock (COO.US): USD$1 billion
• Johnson-and-Johnson (JNJ.US): USD$30.1 billion
• Aerie Pharmaceuticals (AERI.US): USD$-6545000

Bausch + Lomb Corporation financials

Revenue TTM	$4.7 billion
Operating margin TTM	5.44%
Gross profit TTM	$2.2 billion
Return on assets TTM	0.89%
Return on equity TTM	-5.23%
Profit margin	-7.86%
Book value	$18.72
Market Capitalization more info button	$6.3 billion

TTM: trailing 12 months

Bausch + Lomb Corporation share dividends

We're not expecting Bausch + Lomb Corporation to pay a dividend over the next 12 months.

You may also wish to consider:

• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Bausch + Lomb Corporation share price volatility

Over the last 12 months, Bausch + Lomb Corporation's shares have ranged in value from as little as $13.16 up to $21.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bausch + Lomb Corporation's is 0.46. This would suggest that Bausch + Lomb Corporation's shares are less volatile than average (for this exchange).

To put Bausch + Lomb Corporation's beta into context you can compare it against those of similar companies.

• The Cooper Companies IncCommon Stock (COO.US): 0.99
• Johnson-and-Johnson (JNJ.US): 0.518
• Aerie Pharmaceuticals (AERI.US): -0.062

Bausch + Lomb Corporation overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada.

Frequently asked questions

null
What percentage of Bausch + Lomb Corporation is owned by insiders or institutions?
Currently 88.469% of Bausch + Lomb Corporation shares are held by insiders and 10.909% by institutions. How many people work for Bausch + Lomb Corporation?
Latest data suggests 13,000 work at Bausch + Lomb Corporation. When does the fiscal year end for Bausch + Lomb Corporation?
Bausch + Lomb Corporation's fiscal year ends in December. Where is Bausch + Lomb Corporation based?
Bausch + Lomb Corporation's address is: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 What is Bausch + Lomb Corporation's ISIN number?
Bausch + Lomb Corporation's international securities identification number is: CA0717051076